Kyowa Hakko Announces 18.1% Increase in YTD Operating Income and Upward Revision of Its Full Year Forecasts
Tokyo, February 7, 2005 --- Kyowa Hakko Kogyo Co., Ltd. (Kyowa
Hakko)
today announced
continued strong growth in consolidated operating income for the
nine-month period ended December
31, 2004 compared to the first nine months of the previous fiscal year.
Consolidated net sales also
grew and Kyowa Hakko has raised its forecasts for consolidated net
sales, recurring income and net
income for the full year to March 31, 2005.
In the nine months to December 31, 2004 operating income was 26.0
billion yen, up 4 billion yen, or
18.1%, and net sales were 274.8 billion yen, up 4.9 billion yen, or
1.8%, from the comparable period
the year before. Consolidated net income was 15.3 billion yen and net
income per share was 35.66
yen. Kyowa Hakko also performed a share buy-back during the third
quarter of fiscal 2004,
purchasing 7 million shares for 5.2 billion yen.
In the Pharmaceuticals Business, despite the influence of the National
Health Insurance
reimbursement price reductions in April 2004, sales of such products as
Allelock, an antiallergic agent
and Durotep Patch, an analgesic for persistent cancer pain continued to
rise, and volume sales of the
major product Coniel, a treatment for hypertension and angina pectoris,
also performed better than in
the previous comparable fiscal period. In the Bio-Chemicals Business,
sales of amino acids and
nucleic acid related materials for pharmaceuticals, food, and
industrial use declined compared to their
outstanding performance in the comparable period the year before. In
the Chemicals Business,
volume sales of functional products and solvents increased and, as a
result of price revisions in Japan
and good market conditions overseas, net sales increased. In the Food
Business, sales of natural
seasonings including brewed seasonings and bread and cake ingredients
rose, but in processed
foods, sales of OEM products were lower and overall sales of this
segment declined compared to the
first nine months of the previous fiscal year.
Commenting on the results Dr. Yuzuru Matsuda, President of Kyowa Hakko
said 'Business
performance in the nine months ended December 2004 has been good and
has exceeded planned
levels, and as a result we have raised our forecasts for the full year.
In particular the success of the
measures we have taken to strengthen domestic marketing of
pharmaceutical products is helping us
to achieve sustained growth.'
Results for the nine months ended December 31, 2004
(Millions of Yen)
Nine Months to
December 31, 2004
Nine Months to
December 31, 2003
YOY
Change
(%)
FY ended
March 31,
2004
Net sales
274,881
269,890
1.8
348,838
Operating income
26,099
22,095
18.1
26,836
Recurring income
26,081
--
--
24,792
Net income
15,305
--
--
10,017
Net income per share (yen)
35.66
--
--
23.00
Because quarterly results other than those for net sales and operating
income have only been disclosed since the first quarter of fiscal 2004,
year-on-year comparisons are unavailable.
Forecasts for the fiscal year ending March 31, 2005
Fiscal Year ending March 31, 2005
(Millions of Yen)
New forecast (February 7, 2005)
Previous forecast (November 10, 2004)
Net sales
360,000
355,000
Recurring income
29,000
28,000
Net income
16,000
15,000
Forecast net income per share: 37.81 yen
*The above forecasts are based on information available and
assumptions made about a number of uncertain factors
at the time of release of this document that can affect results in the
future. It is possible that actual results are
materially different for a wide variety of reasons.
Contact:
Mr. Kenshiro Honda, Corporate Communications
Department
This document is an English translation of parts
of the Japanese-language original. All financial information has been
prepared
in accordance with generally accepted accounting principles in Japan.
It contains forward-looking statements based on a
number of assumptions and beliefs made by management in light of
information currently available. Actual financial results may
differ materially depending on a number of factors, including
fluctuations in exchange rates, changing economic conditions,
legislative and regulatory developments, delays in new product
launches, and pricing and product initiatives of competitors.